HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

AbstractOBJECTIVE:
To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases.
DATA SOURCES:
Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included.
STUDY SELECTION:
Included trials were randomised controlled trials of patients with malignant disease and bone metastases who were treated with oral or intravenous bisphosphonate compared with another bisphosphonate, placebo, or standard care. All trials measured at least one outcome of skeletal morbidity.
RESULTS:
95 articles were identified; 30 studies fulfilled inclusion criteria. In studies that lasted > or = 6 months, compared with placebo bisphosphonates significantly reduced the odds ratio for fractures (vertebral 0.69, 95% confidence interval 0.57 to 0.84, P < 0.0001; non-vertebral 0.65, 0.54 to 0.79, P < 0.0001; combined 0.65, 0.55 to 0.78, P < 0.0001), radiotherapy (0.67, 0.57 to 0.79, P < 0.0001), and hypercalcaemia (0.54, 0.36 to 0.81, P = 0.003) but not for orthopaedic surgery (0.70, 0.46 to 1.05, P = 0.086) or spinal cord compression (0.71, 0.47 to 1.08, P = 0.113). The reduction in orthopaedic surgery was significant in studies that lasted over a year (0.59, 0.39 to 0.88, P = 0.009). Use of bisphosphonates significantly increased time to first skeletal related event but did not increase survival. Subanalyses showed that most evidence supports use of intravenous aminobisphosphonates.
CONCLUSIONS:
In people with metastatic bone disease bisphosphonates significantly decrease skeletal morbidity, except for spinal cord compression and increased time to first skeletal related event. Treatment should start when bone metastases are diagnosed and continue until it is no longer clinically relevant.
AuthorsJ R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, S R D Johnston
JournalBMJ (Clinical research ed.) (BMJ) Vol. 327 Issue 7413 Pg. 469 (Aug 30 2003) ISSN: 1756-1833 [Electronic] England
PMID12946966 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Diphosphonates
Topics
  • Bone Neoplasms (drug therapy, secondary)
  • Diphosphonates (therapeutic use)
  • Humans
  • Hypercalcemia (etiology)
  • Randomized Controlled Trials as Topic
  • Spinal Cord Compression (prevention & control)
  • Spinal Fractures (prevention & control)
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: